<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Upstream Bio, Inc. — News on 6ix</title>
<link>https://6ix.com/company/upstream-bio-inc</link>
<description>Latest news and press releases for Upstream Bio, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Fri, 17 Apr 2026 11:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/upstream-bio-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835d09f78dffbe2df11f5cf.webp</url>
<title>Upstream Bio, Inc.</title>
<link>https://6ix.com/company/upstream-bio-inc</link>
</image>
<item>
<title>Upstream Bio to Present New Data from Phase 2 VIBRANT Trial of Verekitug at the ATS 2026 International Conference</title>
<link>https://6ix.com/company/upstream-bio-inc/news/upstream-bio-to-present-new-data-from-phase-2-vibrant-trial-of-verekitug-at-the-ats-2026-international-conference</link>
<guid isPermaLink="true">https://6ix.com/company/upstream-bio-inc/news/upstream-bio-to-present-new-data-from-phase-2-vibrant-trial-of-verekitug-at-the-ats-2026-international-conference</guid>
<pubDate>Fri, 17 Apr 2026 11:00:00 GMT</pubDate>
<description>WALTHAM, Mass., April 17, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced two upcoming poster presentations at the American Thoracic Society (ATS) 2026 International Conference in Orlando, FL, on Monday, May 18, 2026. The presentations feature new data from the Phase 2 VIBRANT trial evaluating verekitug, the only known antagonist to the thymi</description>
</item>
<item>
<title>Upstream Bio Highlights Phase 3 Development Strategy for Verekitug and Reports Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/upstream-bio-inc/news/upstream-bio-highlights-phase-3-development-strategy-for-verekitug-and-reports-fourth-quarter-and-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/upstream-bio-inc/news/upstream-bio-highlights-phase-3-development-strategy-for-verekitug-and-reports-fourth-quarter-and-full-year-2025-financial-results</guid>
<pubDate>Thu, 26 Mar 2026 04:00:00 GMT</pubDate>
<description>– Company to pursue Phase 3 development strategy designed to deliver best-in-class efficacy with a high-dose quarterly regimen in broad patient populations in</description>
</item>
<item>
<title>Upstream Bio Presents Additional Analyses from the Phase 2 VIBRANT Trial of Verekitug in Chronic Rhinosinusitis with Nasal Polyps at 2026 AAAAI Annual Meeting</title>
<link>https://6ix.com/company/upstream-bio-inc/news/upstream-bio-presents-additional-analyses-from-the-phase-2-vibrant-trial-of-verekitug-in-chronic-rhinosinusitis-with-nasal-polyps-at-2026-aaaai-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/upstream-bio-inc/news/upstream-bio-presents-additional-analyses-from-the-phase-2-vibrant-trial-of-verekitug-in-chronic-rhinosinusitis-with-nasal-polyps-at-2026-aaaai-annual-meeting</guid>
<pubDate>Sun, 01 Mar 2026 05:00:00 GMT</pubDate>
<description>– Primary endpoint of endoscopic nasal polyp score (NPS) showed reduction of -1.95 (p in new analysis with adjustment for concomitant rescue therapy use – –</description>
</item>
<item>
<title>Upstream Bio to Present Additional Analyses from Phase 2 VIBRANT Trial in Chronic Rhinosinusitis with Nasal Polyps in Late-Breaking Session at AAAAI Annual Meeting 2026</title>
<link>https://6ix.com/company/upstream-bio-inc/news/upstream-bio-to-present-additional-analyses-from-phase-2-vibrant-trial-in-chronic-rhinosinusitis-with-nasal-polyps-in-late-breaking-session-at-aaaai-annual-meeting-2026</link>
<guid isPermaLink="true">https://6ix.com/company/upstream-bio-inc/news/upstream-bio-to-present-additional-analyses-from-phase-2-vibrant-trial-in-chronic-rhinosinusitis-with-nasal-polyps-in-late-breaking-session-at-aaaai-annual-meeting-2026</guid>
<pubDate>Thu, 26 Feb 2026 05:00:00 GMT</pubDate>
<description>– New analyses of efficacy endpoints from the Phase 2 VIBRANT trial of verekitug in CRSwNP to be presented during the late-breaking poster session – WALTHAM,</description>
</item>
<item>
<title>Upstream Bio to Participate in Upcoming March Investor Conferences</title>
<link>https://6ix.com/company/upstream-bio-inc/news/upstream-bio-to-participate-in-upcoming-march-investor-conferences</link>
<guid isPermaLink="true">https://6ix.com/company/upstream-bio-inc/news/upstream-bio-to-participate-in-upcoming-march-investor-conferences</guid>
<pubDate>Wed, 25 Feb 2026 05:00:00 GMT</pubDate>
<description>WALTHAM, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases,</description>
</item>
<item>
<title>Upstream Bio Reports Positive Top-line Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma</title>
<link>https://6ix.com/company/upstream-bio-inc/news/upstream-bio-reports-positive-top-110000410</link>
<guid isPermaLink="true">https://6ix.com/company/upstream-bio-inc/news/upstream-bio-reports-positive-top-110000410</guid>
<pubDate>Wed, 11 Feb 2026 11:00:00 GMT</pubDate>
<description>– Verekitug provided statistically significant and clinically meaningful reductions in annualized asthma exacerbation rate (AAER) with 100 mg q12 and 400 mg q24 week dosing – – Verekitug also delivered clinically meaningful improvements in lung function (FEV1) and exhaled nitric oxide (FeNO) with both dose regimens – – Verekitug was generally well tolerated, with a safety profile consistent with prior studies – – Over 90% of eligible patients have rolled over to the Phase 2 VALOUR long-term exte</description>
</item>
<item>
<title>Upstream Bio to Host Webcast to Report Top-Line Results from the Phase 2 VALIANT Trial of Verekitug in Patients with Severe Asthma</title>
<link>https://6ix.com/company/upstream-bio-inc/news/upstream-bio-host-webcast-report-230000578</link>
<guid isPermaLink="true">https://6ix.com/company/upstream-bio-inc/news/upstream-bio-host-webcast-report-230000578</guid>
<pubDate>Tue, 10 Feb 2026 23:00:00 GMT</pubDate>
<description>– Webcast to be held Wednesday, February 11, 2026, at 8:00 a.m. ET –WALTHAM, Mass., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced it will report top-line results from the Phase 2 VALIANT trial of verekitug, the only known antagonist currently in clinical development that targets and inhibits the thymic stromal lymphopoietin (TSLP)</description>
</item>
<item>
<title>Upstream Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/upstream-bio-inc/news/upstream-bio-present-44th-annual-jp-morgan-healthcare-conference-2026-01-05</link>
<guid isPermaLink="true">https://6ix.com/company/upstream-bio-inc/news/upstream-bio-present-44th-annual-jp-morgan-healthcare-conference-2026-01-05</guid>
<pubDate>Mon, 05 Jan 2026 05:00:00 GMT</pubDate>
<description>WALTHAM, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases,</description>
</item>
<item>
<title>Upstream Bio to Participate in Upcoming December Investor Conferences</title>
<link>https://6ix.com/company/upstream-bio-inc/news/upstream-bio-participate-upcoming-december-investor-conferences-2025-11-25</link>
<guid isPermaLink="true">https://6ix.com/company/upstream-bio-inc/news/upstream-bio-participate-upcoming-december-investor-conferences-2025-11-25</guid>
<pubDate>Tue, 25 Nov 2025 05:00:00 GMT</pubDate>
<description>WALTHAM, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases,</description>
</item>
<item>
<title>Upstream Bio Reports Third Quarter 2025 Financial Results and Highlights Continued Progress</title>
<link>https://6ix.com/company/upstream-bio-inc/news/upstream-bio-reports-third-quarter-2025-financial-results-and-highlights-continued</link>
<guid isPermaLink="true">https://6ix.com/company/upstream-bio-inc/news/upstream-bio-reports-third-quarter-2025-financial-results-and-highlights-continued</guid>
<pubDate>Wed, 05 Nov 2025 05:00:00 GMT</pubDate>
<description>– Positive top-line results from VIBRANT Phase 2 trial of verekitug in CRSwNP reported in September showed statistically significant and clinically meaningful</description>
</item>
<item>
<title>Upstream Bio to Participate in Upcoming November Investor Conferences</title>
<link>https://6ix.com/company/upstream-bio-inc/news/upstream-bio-participate-upcoming-november-investor-conferences-2025-10-31</link>
<guid isPermaLink="true">https://6ix.com/company/upstream-bio-inc/news/upstream-bio-participate-upcoming-november-investor-conferences-2025-10-31</guid>
<pubDate>Fri, 31 Oct 2025 04:00:00 GMT</pubDate>
<description>WALTHAM, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases,</description>
</item>
<item>
<title>Upstream Bio Presents Data Showing Structural and Mechanistic Drivers of Verekitug’s Potent Pharmacodynamic Activity and Differentiated Clinical Profile at European Respiratory Society Congress</title>
<link>https://6ix.com/company/upstream-bio-inc/news/upstream-bio-presents-data-showing-structural-and-mechanistic-drivers-verekitugs</link>
<guid isPermaLink="true">https://6ix.com/company/upstream-bio-inc/news/upstream-bio-presents-data-showing-structural-and-mechanistic-drivers-verekitugs</guid>
<pubDate>Tue, 30 Sep 2025 04:00:00 GMT</pubDate>
<description>– Data show verekitug prevents TSLP binding to the TSLP receptor by occupying ligand binding sites – – Additionally, findings show that verekitug outcompetes</description>
</item>
<item>
<title>Upstream Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum</title>
<link>https://6ix.com/company/upstream-bio-inc/news/upstream-bio-participate-stifel-2025-virtual-immunology-and-inflammation-forum-2025</link>
<guid isPermaLink="true">https://6ix.com/company/upstream-bio-inc/news/upstream-bio-participate-stifel-2025-virtual-immunology-and-inflammation-forum-2025</guid>
<pubDate>Tue, 09 Sep 2025 04:00:00 GMT</pubDate>
<description>WALTHAM, Mass., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases,</description>
</item>
<item>
<title>Upstream Bio Reports Positive Top-Line Results from the Phase 2 VIBRANT Trial of Verekitug for the Treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)</title>
<link>https://6ix.com/company/upstream-bio-inc/news/upstream-bio-reports-positive-top-line-results-phase-2-vibrant-trial-verekitug</link>
<guid isPermaLink="true">https://6ix.com/company/upstream-bio-inc/news/upstream-bio-reports-positive-top-line-results-phase-2-vibrant-trial-verekitug</guid>
<pubDate>Tue, 02 Sep 2025 04:00:00 GMT</pubDate>
<description>– In this 24-week study, VIBRANT met its primary endpoint, with verekitug dosed every 12 weeks leading to a statistically significant and clinically</description>
</item>
<item>
<title>Upstream Bio to Host Conference Call and Webcast to Report Top-Line Data from the Phase 2 VIBRANT Trial of Verekitug in Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)</title>
<link>https://6ix.com/company/upstream-bio-inc/news/upstream-bio-host-conference-call-and-webcast-report-top-line-data-phase-2-vibrant</link>
<guid isPermaLink="true">https://6ix.com/company/upstream-bio-inc/news/upstream-bio-host-conference-call-and-webcast-report-top-line-data-phase-2-vibrant</guid>
<pubDate>Mon, 01 Sep 2025 04:00:00 GMT</pubDate>
<description>– Conference Call and Webcast to be held Tuesday, September 2, 2025, at 8:00 a.m. ET – WALTHAM, Mass., Sept. 01, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc.</description>
</item>
<item>
<title>Upstream Bio Reports Second Quarter 2025 Financial Results and Highlights Continued Progress</title>
<link>https://6ix.com/company/upstream-bio-inc/news/upstream-bio-reports-second-quarter-110000440</link>
<guid isPermaLink="true">https://6ix.com/company/upstream-bio-inc/news/upstream-bio-reports-second-quarter-110000440</guid>
<pubDate>Wed, 06 Aug 2025 11:00:00 GMT</pubDate>
<description>– On track to report top-line data from Phase 2 trial in chronic rhinosinusitis with nasal polyps (CRSwNP) in the third quarter of 2025 – – Completed enrollment in Phase 2 trial in severe asthma in June 2025; top-line data expected in the first quarter of 2026 – – First patient dosed in Phase 2 trial in chronic obstructive pulmonary disease (COPD) in July 2025 – WALTHAM, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for</description>
</item>
<item>
<title>Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease (COPD)</title>
<link>https://6ix.com/company/upstream-bio-inc/news/upstream-bio-announces-first-patient-dosed-phase-2-clinical-trial-verekitug-chronic</link>
<guid isPermaLink="true">https://6ix.com/company/upstream-bio-inc/news/upstream-bio-announces-first-patient-dosed-phase-2-clinical-trial-verekitug-chronic</guid>
<pubDate>Tue, 08 Jul 2025 04:00:00 GMT</pubDate>
<description>– Global Phase 2 clinical trial, VENTURE, to evaluate the efficacy and safety of verekitug administered every 12 or 24 weeks in moderate-to-severe COPD – –</description>
</item>
<item>
<title>Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor</title>
<link>https://6ix.com/company/upstream-bio-inc/news/translational-data-illustrate-mechanism-greater-114500256</link>
<guid isPermaLink="true">https://6ix.com/company/upstream-bio-inc/news/translational-data-illustrate-mechanism-greater-114500256</guid>
<pubDate>Sun, 15 Jun 2025 11:45:00 GMT</pubDate>
<description>– Pharmacology modeling data presented at the European Academy of Allergy & Clinical Immunology (EAACI) Congress describe mechanistic insights for greater potency with verekitug compared to tezepelumab – – Supports potentially differentiated profile of verekitug across a broad range of inflammatory diseases, including severe asthma, chronic obstructive pulmonary disease (COPD) and chronic rhinosinusitis with nasal polyps (CRSwNP) – WALTHAM, Mass., June 15, 2025 (GLOBE NEWSWIRE) -- Upstream Bio,</description>
</item>
<item>
<title>Upstream Bio to Present Mechanistic Insights into Verekitug’s Enhanced Potency via TSLP Receptor Targeting at European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025</title>
<link>https://6ix.com/company/upstream-bio-inc/news/upstream-bio-present-mechanistic-insights-verekitugs-enhanced-potency-tslp-receptor</link>
<guid isPermaLink="true">https://6ix.com/company/upstream-bio-inc/news/upstream-bio-present-mechanistic-insights-verekitugs-enhanced-potency-tslp-receptor</guid>
<pubDate>Thu, 05 Jun 2025 04:00:00 GMT</pubDate>
<description>WALTHAM, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases,</description>
</item>
<item>
<title>Upstream Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference</title>
<link>https://6ix.com/company/upstream-bio-inc/news/upstream-bio-participate-goldman-sachs-46th-annual-global-healthcare-conference-2025</link>
<guid isPermaLink="true">https://6ix.com/company/upstream-bio-inc/news/upstream-bio-participate-goldman-sachs-46th-annual-global-healthcare-conference-2025</guid>
<pubDate>Wed, 04 Jun 2025 04:00:00 GMT</pubDate>
<description>WALTHAM, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases,</description>
</item>
</channel>
</rss>